Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC

Biliary Tract Cancer Clinical Trial

Official title:

A Multicentre, Phase 1B/2 Study of Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic Biliary Tract Cancer.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02992340
• Other study ID #: ASLAN001-007
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: December 13, 2016
• Est. completion date: November 24, 2020

Study information

• Verified date: January 2020
• Source: Aslan Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study intends to evaluate the following objectives in patients with advanced or metastatic biliary tract cancer who have not received systemic therapy for advanced/metastatic disease. Primary Objectives: Phase 1B - To determine the maximum tolerated dose (MTD), as determined by dose-limiting toxicities (DLTs), and to characterise the safety profile of Varlitinib in combination with Gemcitabine and Cisplatin. Phase 2A - To further evaluate the safety and tolerability of Varlitinib in combination with Gemcitabine and Cisplatin at the recommended phase 2 dose (RP2D). - To provide a preliminary assessment of the clinical activity of Varlitinib in combination with Gemcitabine and Cisplatin at the RP2D as measured by Objective Response Rate (ORR) and progression-free survival (PFS) (based on RECIST v1.1) Phase 2B - To compare the efficacy of Varlitinib in combination with Gemcitabine and Cisplatin to placebo in combination with Gemcitabine and Cisplatin as measured by progression-free survival (based on RECIST v1.1).

Description:

In phase 1B part, patients will receive Varlitinib plus Gemcitabine and Cisplatin, and follow a modified 3+3+3 study dose escalation scheme starting from Varlitinib 200 mg BID. The primary objective of the phase 1B part is to determine the MTD of Varlitinib when given in combination with Gemcitabine and Cisplatin, and to characterise the safety profile of the study treatment regimen. Based on the determined MTD and clinical information obtained from phase 1B part of the study, the DSMB will review the safety data and other clinical data, together with the sponsor, determine the MTD as well as the recommended phase 2 dose (RP2D). The sponsor will make a decision when to proceed with the phase 2A part of the study. The phase 2A part of the study is designed as a single arm expansion, enrolling a further 20 patients at the RP2D. The purpose of the phase 2A expansion study is to confirm the safety and tolerability of the RP2D in a larger number of patients, and to provide preliminary estimates of the clinical activity of Varlitinib in combination with Gemcitabine and Cisplatin, prior to embarking on the larger, randomised phase 2B part of the trial. The phase 2B part will be a two-arm, double-blinded, placebo controlled study. Patients will be randomised into 2 arms to receive Varlitinib plus Gemcitabine and Cisplatin, or placebo plus Gemcitabine and Cisplatin. The primary endpoint of the phase 2B part is progression-free survival (PFS). The randomisation will be stratified by primary tumour location (gall bladder or non-gall bladder). Patient screening activities including informed consent and study eligibility verification will be performed within 21 days prior to first dose of the study medication. Radiological imaging to assess the disease status will be performed at baseline and every 6 weeks from Cycle 1 Day 1. Blood samples will be taken during the screening phase, treatment period until end of treatment. Patients will be required to complete safety follow-up within 28 days after the last administration of study medication.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 204
• Est. completion date: November 24, 2020
• Est. primary completion date: June 16, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Patient of respective country's legal age or older at the time of written informed consent.

2. Patient must be able to understand and willing to provide informed consent for participation in the study and donation of tumour tissue (archival or fresh) for evaluation of relevant exploratory endpoints.

3. Patient must have histologically or cytologically confirmed advanced (unresectable) or metastatic biliary tract cancer, including intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or carcinoma of the Ampulla of Vater, with no prior systemic therapy for advanced/metastatic disease. This includes clinical diagnosis of biliary tract cancer with histological confirmation of adenocarcinoma.

4. For phase 1B and 2A only: Presence of radiologically measured disease with at least one, not previously irradiated, measurable lesion according to RECIST v.1.1.

5. No evidence of clinically significant biliary duct obstruction, unless obstruction is controlled by local treatment or, in whom the biliary tree can be decompressed by endoscopic or percutaneous stenting with subsequent reduction in bilirubin to below or equal to 1.5 x upper level of normal (ULN).

6. Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

7. Patient with adequate organ and haematological function prior to first dose of study medication: a. Haematological function, as follows: i. Absolute neutrophil count (ANC) = 1.5 x 109/L ii. Platelet count = 100 x 109/L iii. Haemoglobin level = 10 g/dl b. Renal functions, as follows: i. Serum creatinine = 1.5x ULN or eGFR > 60 ml/min/1.73m2 c. Hepatic function, as follows: i. Total bilirubin = 1.5 x ULN ii. AST and ALT = 5 x ULN

Exclusion Criteria:

1. Patients with radiation or local treatment 6 weeks prior to screening for the target lesion(s).

2. Patients with major surgical procedures within 21 days prior to screening.

3. Patients with known brain metastases.

4. Patients with malabsorption syndrome, diseases significantly affecting gastrointestinal function, resection of the stomach or small bowel, or difficulty in swallowing and retaining oral medications which in the opinion of the Investigator could jeopardize the validity of the study results. Any extent of stomach resection will be excluded.

5. Pre-existing peripheral sensory neuropathy = grade 2 according to CTCAE (v.4.03).

6. Patients with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, diabetes, hypertension, or psychiatric illness/social situations that would limit compliance with study requirements.

7. Patients with any history of other malignancy unless in remission for more than 1 year prior to screening (Non-melanoma skin carcinoma and carcinoma-in-situ of uterine cervix treated with curative intent is not exclusionary).

8. Patients with a known history of HIV, decompensated cirrhosis, HCV infection, and for phase 1B: HBV infection with detectable HBV deoxyribonucleic acid (DNA) or abnormal transaminase; for phase 2A & 2B: HBV infection with HBV DNA exceeding 2000 IU/mL.

9. Any history or presence of clinically significant cardiovascular, respiratory, hepatic, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease or any other condition, which, in the opinion of the investigator, could jeopardise the safety of the patient or the validity of the study results.

10. Patients with known history of drug addiction within last 1 year.

11. Patients who may need continuous treatment with proton pump inhibitors or strong CYP3A4 inhibitors during the study period.

12. Female patients who are pregnant or breast-feeding.

13. Patients who have received any investigational drug (or have used an investigational device) within the last 14 days before receiving the first dose of study medication.

14. Patients who have received immunotherapy for cancer, including but not limited to immune checkpoint inhibitors, monoclonal antibody, cancer vaccine, and cell therapy.

15. Patient with unresolved or unstable serious toxicity (= CTCAE 4.03 Grade 2) from prior administration of another investigational drug and/or prior cancer treatment.

16. Have a history of (non-infectious) pneumonitis that required steroids or current pneumonitis, or have a history of interstitial lung disease or current interstitial lung disease.

Related Conditions & MeSH terms

• Biliary Tract Cancer
• Biliary Tract Neoplasms

Intervention

Drug:
• Varlitinib
Per oral (PO) Varlitinib BID (starting dose at 200 mg BID)
• Cisplatin
On D1 and D8, every 3 weeks. Cisplatin (25 mg per square meter of body surface area) in 1 litre of 0.9% saline with 20 mmol of potassium chloride and 8 mmol of magnesium sulfate intravenous (IV) infusion for 2 hours, followed by 500 mL of 0.9% saline over 30 minutes before the administration of Gemcitabine
• Gemcitabine
On D1 and D8, every 3 weeks. Gemcitabine (1000 mg per square meter of body surface area) as a 30-minute infusion.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Aslan Pharmaceuticals

Countries where clinical trial is conducted

Korea, Republic of,  Singapore,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1B: Maximum tolerated dose (MTD) of Varlitinib	To determine the maximum tolerated dose (MTD), as determined by dose-limiting toxicities (DLTs), and to characterise the safety and tolerability profile of Varlitinib as determined by the adverse events in combination with Gemcitabine and Cisplatin.	DLT period is 3 weeks
Primary	Phase 1B: Safety and toxicity	Determined by the adverse events.	Through study duration, estimated 3 years
Primary	Phase 2A: Safety and tolerability	Determined by adverse events	Through study duration, estimated 3 years
Primary	Phase 2A: Safety and tolerability	Determined by safety parameters (including vital signs, ECG parameters, clinical laboratory tests)	Through study duration, estimated 3 years
Primary	Phase 2A: Safety and tolerability	Other measures of tolerability such as dose interruptions, treatment exposure and dose intensity.	Through study duration, estimated 3 years
Primary	Phase 2A: Objective Response Rate (ORR)	ORR is defined as the number (%) of patients with at least one visit response of CR or PR. Data obtained up until the earlier of progression or the last evaluable assessment prior to starting subsequent therapy, will be included in the assessment of ORR.	Through study duration, estimated 3 years
Primary	Phase 2A: Progression Free Survival (PFS)	PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined in accordance with the RECIST v1.1 criteria and will be derived programmatically.	Through study duration, estimated 3 years
Primary	Phase 2B: Progression Free Survival (PFS)	PFS is defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined in accordance with the RECIST v1.1 criteria and will be derived programmatically based on data from the Independent Central Review (ICR) of radiological data.	Through study duration, estimated 3 years
Secondary	Objective Response Rate (ORR)(Phase 1B)	ORR is defined as the number (%) of patients with at least one visit response of CR or PR. Data obtained up until the earlier of progression or the last evaluable assessment prior to starting subsequent therapy, will be included in the assessment of ORR.	Through study duration, estimated 3 years
Secondary	Objective Response Rate (Phase 2B)	ORR is defined as the number (%) of patients with at least one visit response of CR or PR. Data obtained up until progression or the last evaluable assessment in the absence of progression, will be included in the assessment of ORR.	Through study duration, estimated 3 years
Secondary	Disease control rate (DCR) (Phase 1B, Phase 2A and Phase 2B)	DCR is defined as the number (%) of patients with at least one visit response of CR or PR, or with stable disease for a minimum of twelve weeks (- 5 days) from randomisation (Phase 2B) or starting treatment (Phase 1B and Phase 2A). For Phase 2B, data obtained up until progression, or last evaluable assessment in the absence of progression, will be included in the assessment of DCR.	Through study duration, estimated 3 years
Secondary	Duration of response (DoR) (Phase 1B, Phase 2A and Phase 2B)	DoR is defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression.	Through study duration, estimated 3 years
Secondary	Overall Survival (OS) (Phase 2A and Phase 2B only)	OS is defined as time from the start of treatment (Phase 2A) or randomisation (Phase 2B) until death by any cause.	Through study duration, estimated 3 years
Secondary	Incidence of AEs (Phase 2B)	Changes from baseline in safety parameters (including vital signs, ECG parameters, clinical laboratory tests) as categorized in accordance to CTCAE v4.03	Through study duration, estimated 3 years
Secondary	Pharmacokinetics of Varlitinib (Phase 1B)	Maximum plasma concentration (Cmax)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Varlitinib (Phase 1B)	Time to Cmax (tmax)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Varlitinib (Phase 1B)	Area under the plasma concentration-time curve from 0 to 6 hours (AUC0-6), and area under the plasma concentration-time curve from 0 to 12 hours (AUC0-12).	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Varlitinib (Phase 1B)	Pre-dose concentration (Ctrough)	Cycle 2 Day 1
Secondary	Pharmacokinetics of Varlitinib (Phase 1B)	Accumulation ratio of AUC0-6 (Day 22) compared to AUC0-6 (Day 1) (RacAUC0-6), accumulation ratio of AUC0-12 (Day 22) compared to AUC0-12 (Day 1) (RacAUC0-12)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Varlitinib (Phase 1B)	Accumulation ratio of Cmax (Day 22) compared to Cmax (Day 1) (RacCmax).	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Varlitinib (Phase 1B)	Accumulation ratio of Cmax (Day 22) compared to Cmax (Day 1) (RacCmax)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Varlitinib (Phase 2B)	Maximum plasma concentration (Cmax)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Varlitinib (Phase 2B)	Time to Cmax (tmax)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Varlitinib (Phase 2B)	Area under the plasma concentration-time curve from 0 to 6 hours (AUC0-6), and area under the plasma concentration-time curve from 0 to 12 hours (AUC0-12)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Varlitinib (Phase 2B)	Pre-dose concentration (Ctrough)	Cycle 2 Day 1
Secondary	Pharmacokinetics of Varlitinib (Phase 2B)	Accumulation ratio of AUC0-6 (Day 22) compared to AUC0-6 (Day 1) (RacAUC0-6), accumulation ratio of AUC0-12 (Day 22) compared to AUC0-12 (Day 1) (RacAUC0-12)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Varlitinib (Phase 2B)	Accumulation ratio of Cmax (Day 22) compared to Cmax (Day 1) (RacCmax)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Gemcitabine, dFdU (gemcitabine metabolite) and Cisplatin (Phase 2B)	Maximum plasma concentration (Cmax)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Gemcitabine, dFdU (gemcitabine metabolite) and Cisplatin (Phase 2B)	Time to Cmax (tmax)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Gemcitabine, dFdU (gemcitabine metabolite) and Cisplatin (Phase 2B)	Last measurable concentration (Clast)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Gemcitabine, dFdU (gemcitabine metabolite) and Cisplatin (Phase 2B)	Terminal half-life (t1/2)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Gemcitabine, dFdU (gemcitabine metabolite) and Cisplatin (Phase 2B)	Mean residence time (MRT)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Gemcitabine, dFdU (gemcitabine metabolite) and Cisplatin (Phase 2B)	Volume of distribution at the terminal phase (Vz) and volume of distribution at the steady-state (Vss)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Gemcitabine, dFdU (gemcitabine metabolite) and Cisplatin (Phase 2B)	Plasma clearance (Cl)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Gemcitabine, dFdU (gemcitabine metabolite) and Cisplatin (Phase 2B)	Area under the plasma concentration-time curve from 0 to t (AUC0-t), and area under the plasma concentration-time curve from 0 to infinite (AUC0-inf)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Gemcitabine, dFdU (gemcitabine metabolite) and Cisplatin (Phase 2B)	Accumulation ratio of AUC0-inf (Day 22) compared to AUC0-inf (Day 1) (RacAUC0-inf)	Cycle 1 Day 1 and Cycle 2 Day 1
Secondary	Pharmacokinetics of Gemcitabine, dFdU (gemcitabine metabolite) and Cisplatin (Phase 2B)	Accumulation ratio of Cmax (Day 22) compared to Cmax (Day 1) (RacCmax)	Cycle 1 Day 1 and Cycle 2 Day 1